Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €6.18 EUR
Change Today -0.143 / -2.26%
Volume 0.0
F6T On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 10:04 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

fate therapeutics inc (F6T) Snapshot

Open
€6.20
Previous Close
€6.32
Day High
€6.20
Day Low
€6.18
52 Week High
07/14/15 - €7.27
52 Week Low
12/16/14 - €2.78
Market Cap
170.5M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
27.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FATE THERAPEUTICS INC (F6T)

Related News

No related news articles were found.

fate therapeutics inc (F6T) Related Businessweek News

No Related Businessweek News Found

fate therapeutics inc (F6T) Details

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular therapeutics for the treatment of severe, life-threatening diseases. It has a platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules. The company focuses primarily on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of hematologic malignancies, rare genetic disorders, and diseases resulting from the dysregulation of the immune system. The company’s lead product candidate is ProHema, an ex vivo programmed hematopoietic cellular therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies in adults; in Phase Ib clinical development for hematologic malignancies in pediatric patients; and in Phase Ib clinical development for inherited metabolic disorders in pediatric patients. It is also developing a triple modulator combination of pharmacologic modulators that programs human CD34+ cells to express high levels of PD-L1, a key immunosuppressive protein; and in vivo therapeutic potential of PD-L1 programmed CD34+ cells to selectively home to sites of, and suppress, T cell proliferation, and cytokine production. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

50 Employees
Last Reported Date: 03/12/15
Founded in 2007

fate therapeutics inc (F6T) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $350.0K
Chief Operating Officer and Chief Financial O...
Total Annual Compensation: $310.0K
Compensation as of Fiscal Year 2014.

fate therapeutics inc (F6T) Key Developments

Fate Therapeutics, Inc. expected to report Q2 2015 results on August 4, 2015. This event was calculated by Capital IQ (Created on July 31, 2015).

Fate Therapeutics, Inc. expected to report Q2 2015 results on August 4, 2015. This event was calculated by Capital IQ (Created on July 31, 2015).

Fate Therapeutics Enters into Research Collaboration with University of Minnesota on Development of Natural Killer Cell-Based Immuno-Oncology Candidates

Fate Therapeutics entered into a research collaboration with the University of Minnesota focused on the development of natural killer (NK) cell-based immuno-oncology candidates. Fate Therapeutics will leverage the University's pioneering work on NK cell-based therapies, as well as its own cell-programming and stem-cell technology platform to develop 'off-the-shelf' candidates with anti-tumour activity. The collaboration will focus on two main therapeutic projects, one related to optimisation of 'adaptive' NK cells, and the other focused on utilisation of induced pluripotent stem cells (iPSCs) to derive NK cell-based candidates. Based on the terms of the agreement, Fate Therapeutics has the option to obtain exclusive patent rights to candidates resulting from the collaboration.

Fate Therapeutics, Inc. Appoints Dr. Stewart Abbot as Vice President, Translational Research

Fate Therapeutics, Inc. announced that it has named Dr. Stewart Abbot as Vice President, Translational Research, effective immediately. Dr. Abbot comes to Fate Therapeutics from Celgene Corporation, where he most recently served as Executive Director, Integrative Research at Celgene Cellular Therapeutics. In his role at Fate Therapeutics, Dr. Abbot will be responsible for charting the advancement of the company's innovative pipeline of programmed cellular immunotherapeutics from discovery into early clinical development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
F6T:GR €6.18 EUR -0.143

F6T Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for F6T.
View Industry Companies
 

Industry Analysis

F6T

Industry Average

Valuation F6T Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FATE THERAPEUTICS INC, please visit www.fatetherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.